Annovis Bio Inc. (NYSE: ANVS) has announced encouraging progress in its Phase 3 clinical trial for early Alzheimer’s disease, along with improved financial results for the second quarter of 2025. The trial, identified as NCT06709014, has now secured 76 U.S. sites, with 46 actively enrolling patients. As of the reporting date, 38 patients have been dosed and nearly 200 are in the screening process. The enrollment is on track, with a screen failure rate of 50%, which aligns with expectations for Alzheimer’s trials.
Recent achievements by the company include the presentation of four scientific posters at the AAIC 2025 conference, the appointment of a director of biostatistics, and the hosting of a trial update webcast. Additionally, Annovis Bio has strengthened its intellectual property portfolio by securing global coverage for crystal buntanetap, a key component in its therapeutic pipeline for neurodegenerative diseases.
Financially, the company showed notable improvement. Cash and equivalents rose to $17.1 million as of June 30, 2025, up from $10.6 million at the end of 2024. Research and development expenses decreased to $5.2 million from $5.8 million in the prior year quarter, while general and administrative expenses dropped to $1.1 million from $2.0 million. This financial discipline contributed to a narrowing of the net loss per share to $0.32 from $0.44.
The progress in the Phase 3 trial and improved financial position underscore Annovis Bio’s commitment to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. For more detailed information, visit https://ibn.fm/iO1TH.
